Iopamidol API Manufacturers & Suppliers

Iopamidol (CAS 60166-93-0) is a nonionic, low‑osmolar iodinated contrast agent widely used to enhance visualization during diagnostic imaging procedures. Its primary clinical applications include intravascular administration for computed tomography and angiography, as well as intrathecal and cavity administration when appropriate formulations are used. The compound is an iodobenzene derivative containing three iodine atoms on a benzoic acid core, contributing to its radiodensity.

Pharmacologically, iopamidol acts as a passive radiographic marker. Following administration, the tri‑iodinated aromatic structure absorbs X‑rays, increasing contrast between vascular or anatomical structures and surrounding tissues. The molecule does not undergo receptor-mediated interactions and exhibits minimal protein binding.

Absorption is route dependent. After intravenous administration, distribution is largely confined to the extracellular fluid compartment. Iopamidol is not metabolized and is eliminated almost entirely through renal excretion via glomerular filtration, with a plasma half‑life of approximately two hours in individuals with normal renal function. Clearance is significantly prolonged in renal impairment, necessitating careful risk assessment.

Safety considerations focus on the potential for contrast‑induced nephrotoxicity, hypersensitivity reactions, and adverse events associated with intrathecal use. Low osmolarity reduces but does not eliminate the risk of renal stress or neurotoxicity. Adequate hydration, screening for renal dysfunction, and avoidance of excessive cumulative iodine load are standard precautions. Adverse reactions may include nausea, warmth, headache, or transient hemodynamic changes, with rare but serious anaphylactoid responses.

Iopamidol is marketed in multiple concentration‑specific formulations for imaging applications and is used globally in hospital and diagnostic center settings. Product selection depends on route of administration and required iodine concentration.

For API procurement, suppliers should provide verifiable data on assay purity, iodine content uniformity, osmolality profile, and residual solvent levels. Compliance with major pharmacopeial monographs and validated control of iodinated impurity profiles are essential to ensure consistent performance in finished contrast media products.